- Quality Pipeline
- Substantial upcoming milestone payments
- Continual phase study reports (Lets hope for good news)
- Undervalued potential
Lets not forget the patents owned for this new form of life saving drugs. Still at $22 - $24 at year end, We'll see what happens when Kynamro gets into patients hands. Took a very small risk and sold a few June $21 puts yesterday. Money where my mouth is, believe the stock stays at least in the $20 range.
Again, congrats to those who purchased shares last week. Doesn't it feel good to own something that's best of breed with a bright future :)
Curious what the rest of the actual stock holders think.